Publications Archives - Page 6 of 27 - Swiss Vaccine Research Institute

Volk, V., Theobald, S. J., Danisch, S., Khailaie, S., Kalbarczyk, M., Schneider, A., Bialek-Waldmann, J., Kronke, N., Deng, Y., Eiz-Vesper, B., Dragon, A. C., von Kaisenberg, C., Lienenklaus, S., Bleich, A., Keck, J., Meyer-Hermann, M., Klawonn, F., Hammerschmidt, W., Delecluse, H. J., Munz, C., Feuerhake, F., and Stripecke, R.

Jan 12, 2021 | Publications

PD-1 Blockade Aggravates Epstein-Barr Virus+ Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4+ T Cell Dysregulations

Zdimerova, H., Murer, A., Engelmann, C., Raykova, A., Deng, Y., Gujer, C., Ruhl, J., McHugh, D., Caduff, N., Naghavian, R., Pezzino, G., Capaul, R., Zbinden, A., Ferlazzo, G., Lunemann, J. D., Martin, R., Chatterjee, B., and Munz, C.

Jan 1, 2021 | Publications

Attenuated immune control of Epstein-Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15

Godot V., Tcherakian C., Gil L., Cervera-Marzal I., Li G., Cheng L., Ortonne N., Lelièvre J.D., Pantaleo G., Fenwick C., Centlivre M., Mouquet H., Cardinaud S., Zurawski S.M., Zurawski G., Milpied P., Su L., Lévy Y.

Nov 30, 2020 | Publications

TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice

Moorlag S.J.C.F.M., Rodriguez-Rosales Y.A., Gillard J., Fanucchi S., Theunissen K., Novakovic B., de Bont C.M., Negishi Y., Fok E.T., Kalafati L., Verginis P., Mourits V.P., Koeken V.A.C.M., de Bree L.C.J., Pruijn G.J.M., Fenwick C., van Crevel R., Joosten L.A.B., Joosten I., Koenen H., Mhlanga M.M., Diavatopoulos D.A., Chavakis T., Netea M.G.

Nov 17, 2020 | Publications

BCG Vaccination Induces Long-Term Functional Reprogramming of Human Neutrophils

Lévy Y., Lacabaratz C., Ellefsen-Lavoie K., Stöhr W., Lelièvre J.D., Bart P.A., Launay O., Weber J., Salzberger B., Wiedemann A., Surenaud M., Koelle D.M., Wolf H., Wagner R., Rieux V., Montefiori D.C., Yates N.L., Tomaras G.D., Gottardo R., Mayer B., Ding S., Thiébaut R., McCormack S., Chêne G., Pantaleo G.

Jun 26, 2020 | Publications

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

Moodie Z., Walsh S.R., Laher F., Maganga L., Herce M.E., Naidoo S., Hosseinipour M.C., Innes C., Bekker L.G., Grunenberg N., Mann P., Yu C., deCamp A.C., Miner M.D., Yates N.L., Heptinstall J., Mkhize N.N., Dintwe O., Frahm N., Cohen KW., Allen M., Hutter J., Wagner R., Pantaleo G., McElrath M.J., Tomaras G.D., Morris L., Montefiori D.C., Andersen-Nissen E., Gray G.E., Gilbert P.B., Kublin J.G.; NIAID HVTN 100 and HVTN 111 trial teams.

May 22, 2020 | Publications

Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials

« Older Entries

Next Entries »